4.7 Article

Implications of antibiotics use during the COVID-19 pandemic: present and future

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 75, 期 12, 页码 3413-3416

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkaa350

关键词

-

资金

  1. RD Project CAREBIO2-Comparative assessment of antimicrobial resistance in environmental biofilms through proteomics-toward innovative theranostic biomarkers - European Regional Development Fund (ERDF) through the Northern Regional Operational Program (NOR [NORTE-01-0145FEDER-030101, PTDC/SAU-INF/30101/2017]
  2. Foundation for Science and Technology (FCT)
  3. Associate Laboratory for Green Chemistry-LAQV - national funds from FCT/MCTES [UID/QUI/50006/2019]
  4. FCT [SFRH/BD/137947/2018]

向作者/读者索取更多资源

COVID-19 is caused by the SARS-CoV-2 virus, which has infected more than 4 million people with 278 892 deaths worldwide as of 11 May 2020. This disease, which can manifest as a severe respiratory infection, has been declared as a public health emergency of international concern and is being treated with a variety of antivirals, antibiotics and antifungals. This article highlights the administration of antimicrobials in COVID-19 patients worldwide, during the 2019-20 pandemic. It is imperative to be aware of the unreported amounts of antibiotics that have been administered worldwide in just a few months and a marked increase in antimicrobial resistance should therefore be expected. Due to the Lack of data about antimicrobial use during this pandemic, the global impact on the emergence of new antimicrobial resistance is as yet unknown. This issue must be at the forefront of public health policymaking and planning in order that we are prepared for the potentially severe consequences for human and animal health and the environment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据